Ramit Sharma, MD
Pulmonary Disease · Phoenix, AZNPI 1659374593
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.6%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 45 manufacturers reported payments, led by United Therapeutics Corporation at 30.1% of the total. Reporting peaked in 2019 at $20,633 and has fallen 81.9% since, to $3,740 in 2024. Among pulmonary disease clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,107 payments — averaging $58.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$19K
- Bayer$16K
- Mylan Specialty L.p.$12K
- GSK$3K
- AstraZeneca$3K
- Genentech USA, Inc.$2K
- plus $10K from 39 others
What the payments were for
- Consulting fees$7,59412%
- Speaking & faculty fees$36,51257%
- Travel & lodging$1890%
- Food & beverage$19,84931%
- Education$3991%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$64,543 in reported general payments places this provider in the 90th percentile of 250 pulmonary disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 83 | $1,063,365 |
| AdempasRiociguat | 40 | $551,356 |
| UptraviSelexipag | 18 | $322,386 |
| OfevNintedanib Esylate | 18 | $234,415 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 132 | $125,755 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 54 | $42,912 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 46 | $32,446 |
| Breo ElliptaFluticasone/Vilanterol | 66 | $30,909 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 32 | $21,810 |
| Spiriva RespimatTiotropium Bromide | 15 | $13,119 |
| SymbicortBudesonide/Formoterol Fumarate | 33 | $11,470 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 32 | $5,842 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 183 | $5,673 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 24 | $2,597 |
| Ventolin HfaAlbuterol Sulfate | 20 | $1,758 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $1,253 | $1,385,751101 claims |
| BayerAdempas | $15,660 | $551,35640 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $1,050 | $279,98179 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $3,012 | $178,474230 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $2,863 | $54,38287 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 250 pulmonary disease providers in Arizona.
Other pulmonary disease in Phoenix
- Rajat WaliaPhoenix$748K
- Brian PorvinPhoenix$276K
- Abid KhokarPhoenix$262K
- Tony HodgesPhoenix$248K
- Mark GotfriedPhoenix$196K
- Rajeev SaggarPhoenix$161K
- Gregory AhearnPhoenix$144K
- Jagruti PatelPhoenix$141K
- Ali SaeedPhoenix$138K
- Bhuvin BuddhdevPhoenix$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.